Upadacitinib showed promising results in achieving clinical and endoscopic remission in people with moderate to severe Crohn ...

艾伯维宣布，欧盟委员会（EC）已批准RINVOQ®（upadacitinib；15mg，每日一次）用于治疗巨细胞动脉炎（GCA）成人患者。RINVOQ成为欧盟、冰岛、列支敦士登以及挪威目前首个且唯一获批用于治疗GCA成年患者的口服JAK抑制剂。

A total of 209 patients received upadacitinib at a dose of 15 mg, 107 received upadacitinib at a dose of 7.5 mg, and 112 received placebo; 70% of the patients had new-onset giant-cell arteritis ...

为探究关节炎治疗及药物疗效问题，研究人员开展了关于 Tr14 凝胶治疗急性踝关节扭伤、肠道微生物群与髋关节炎关系、Upadacitinib 治疗巨细胞动脉炎（RZA）、Baricitinib 单药治疗类风湿关节炎（RA）的研究。结果显示各研究成果显著，为关节炎治疗提供新方向和 ...

A global clinical trial is underway to evaluate two anti-inflammatory drugs as potential treatments for long COVID, aiming to ...

The European Commission (EC) has granted marketing authorisation for AbbVie's once-a-day treatment Rinvoq (upadacitinib) 15mg for adults with giant cell arteritis (GCA). It is the first and only oral ...

In the Phase III SELECT-GCA trial, Rinvoq (upadacitinib) 15 mg with a 26-week glucocorticoid taper significantly improved ...

The study was an open-label extension of two phase 3 studies. Response to upadacitinib was maintained, with responses of “similar magnitude” after switching from placebo. Upadacitinib sustains ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

Spanning four continents and enrolling hundreds of people, a new clinical trial led by scientists from Western and the Schmidt Initiative for Long ...